Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
By R. Andtbacka, H. Kaufman, F. Collichio, T. Amatruda, N. Senzer, J. Chesney, K. Delman, L. Spitler, I. Puzanov, S. Agarwala and 19 more. Journal of Clinical Oncology, 2015
2,318 citations recorded by the source corpus.
Subfields: Biotechnology, Genetics, Oncology
View Paper: https://www.semanticscholar.org/paper/80bd4b0e40d4fa08bb53b7caf0a872fc86d05ddb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
Citations in the corpus
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, methodology): “Radiation therapy, electrochemotherapy [29] or intralesional therapy, with replicating T-Vec [30], may also be used [V, D], [27, 28]. treatment of systemic metastatic disease (stage IV) New therapeutic strategies, such as immunotherapy, that utilise antibodies that bind to checkpoint inhibitors of T”
- Immunotherapy for glioma: current management and future application. (2020, neutral): “In 2015, a genetically modi fi ed herpes simple virus (HSV), tali-mogene laherparepvec (T-VEC), was approved by the FDA for the treatment of metastatic melanoma [98].”
- Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, methodology): “as well as stratification and analysis, are often based on the presence/absence of CNS disease.(6-20,73,74) Therefore, this additional level of granularity in the M category “maps” bet-”
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (2017, neutral): “The benefit of increased responses was achieved with a low rate of toxicities, most of which were expected with the single-agent use of talimogene laherparepvec or pembrolizumab (Andtbacka et al., 2015; Ribas et al., 2016).”